Amendment No. 1 to Schedule 13D for Semnur Pharmaceuticals, Inc.

This Amendment No. 1 to Schedule 13D is filed by Scilex Holding Company and Scilex, Inc. to correct the CIK code and issuer name used in the original filing dated September 26, 2025. The filing reports the beneficial ownership of common stock of Semnur Pharmaceuticals, Inc. following a business combination completed on September 22, 2025. The business combination involved the merger of Semnur Pharmaceuticals, Inc. with Denali Capital Acquisition Corp., resulting in the issuance of common stock to Scilex Holding Company and its subsidiaries. The filing also details various agreements, including a Merger Agreement, Debt Exchange Agreement, and Convertible Note, which facilitated the transactions. Additionally, the filing reports the transfer of 12,500,000 shares of common stock to a third party post-business combination.